Abstract
High mobility group B1 (HMGB1) is a protein that is released from dying cancer cells in the context of immunogenic cell death (ICD). A recent study performed on patients with head and neck squamous cell carcinomas (HNSCC) reports that a chemoradiotherapy-induced increase in circulating HMGB1 levels predicts favorable outcome, echoing prior studies on neoadjuvant treatment of breast and rectal cancer in which the dynamics of HMGB1 plasma levels also have prognostic value. Hence, a therapy-induced rise in HMGB1 may be interpreted as a clinical sign of ICD and therapeutic response.
Funding Information
  • Ile de France and Institut National du Cancer
  • Ligue contre le Cancer (équipes labellisées, Program “Equipe labelisée LIGUE” (EL2016.LNCC)
  • Agence national de la recherche
  • Association pour la Recherche sur le Cancer
  • Association “Le Cancer du Sein, Parlons-en!”
  • Cancéropôle Ile-de-France
  • Chancelerie des universités de Paris
  • Fondation pour la Recherche Médicale
  • Elior
  • European Research Area Network on Cardiovascular Diseases
  • Gustave Roussy Odyssea
  • the European Union Horizon 2020 Project Oncobiome
  • Fondation Carrefour
  • Inca
  • Inserm
  • Institut Universitaire de France
  • Leducq Foundation
  • the LabEx Immuno-Oncology
  • the RHU Torino Lumière
  • The SEERAVE Foundation
  • the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination
  • the SIRIC Cancer Research and Personalized Medicine

This publication has 10 references indexed in Scilit: